Asthma Management Handbook
Close window

Table. Reviewing and adjusting preventer treatment for children aged 6–11 years

Initial treatment Management options at a review of initial treatment after a trial of 4-6 weeks
Treatment response No or partial response

Montelukast
 

Continue treatment

Set review date (e.g. 6 months)

Stop treatment and start treatment with an inhaled corticosteroid, starting with a low dose

Inhaled corticosteroid
(low dose)

Continue regular treatment at low dose

Set review date (e.g. 6 months)

Consider one of the following options:

Add montelukast in addition to inhaled corticosteroid§

Increase the dose of inhaled corticosteroid; reassess within 12 weeks*

Switch to combination long-acting beta2agonist/inhaled corticosteroid#
  • Advise parents/carers about potential adverse behavioural and/or neuropsychiatric effects of montelukast

Treatment response: Symptoms well controlled and no treatment-related adverse effects

No or partial response: Symptom control not achieved with initial treatment after verifying treatment was taken as intended

‡ Before considering a change in the treatment regimen:

  • review the diagnosis, adherence and inhaler technique
  • review modifiable triggers
  • consider referral to a specialist (e.g. paediatric respiratory physician or paediatrician, if available) for assessment.

§ PBS status as at March 2019: Montelukast treatment is not subsidised by the PBS for people aged 15 years or over.

* Timing of review depends on individual child’s trigger factors

# TGA-approved indications and PBS listings for combination long-acting beta2agonist/inhaled corticosteroid differ between age groups – check before prescribing

Last reviewed version 2.0

Asset ID: 26